The Lupus Analysis Alliance and its medical analysis affiliate Lupus Therapeutics at this time introduced the launch of the Lupus Landmark Examine, a groundbreaking observational analysis examine to speed up the event of personalised therapies for individuals residing with lupus. The Lupus Landmark Examine, the most important examine of its type in lupus, will prospectively recruit and longitudinally observe 3,500 adults recognized with systemic lupus erythematosus (SLE). The Lupus Landmark Examine is a key part of the Lupus Nexus, a state-of-the-art, patient-centric, collaborative analysis useful resource.
The goal of the Lupus Nexus is to remodel lupus analysis and drug improvement via unprecedented info trade capabilities. The platform will present a collaborative answer that’s inclusive of various affected person populations disproportionally affected by lupus. The Lupus Nexus can be a supply of extremely curated medical information, affected person reported information, organic samples, and uncooked analyzed information to catalyze international collaboration, innovation, and precision drugs approaches in lupus.
We’re thrilled to launch the Lupus Landmark Examine as the primary part of the Lupus Nexus. This can be a important milestone for the lupus neighborhood and a chance to allow main breakthroughs in our understanding and therapy of lupus. We’re immensely grateful to all our collaborative companions who’ve introduced us to this stage, together with individuals with lupus, clinicians, researchers, business, authorities, and non-profit entities.”
Teodora Staeva, PhD, VP and Chief Scientific Officer of the Lupus Analysis Alliance
Folks with lupus have performed a key function within the improvement of the Lupus Nexus and can proceed to be on the core of this effort via their participation within the Lupus Landmark Examine. Their engagement will generate the information wanted to drive patient-centric therapies in addition to permit individuals larger visibility into their very own private well being information.
“Not solely is it necessary to know lupus from the vantage level of every particular person residing with this illness, however it’s necessary that researchers and sufferers have a voice in these necessary initiatives,” stated Ruth Wilson, member of the Lupus Nexus Steering Committee and the Govt Committee of LRA’s Younger Leaders Board. “It is thrilling to see this examine come to life and an honor to offer my perspective and suggestions as each a researcher and lupus affected person advocate.”
The Lupus Nexus will assist each discovery and medical improvement analysis. Scientists will correlate deidentified information from the Landmark Examine with analyzed biosample information to establish or validate drug targets, biomarkers, and speculation, with the purpose of finally understanding illness heterogeneity and growing more practical diagnostic, prognostic, and therapy approaches for lupus.
“A crucial a part of unlocking new insights into this advanced illness is larger collaboration and information sharing among the many international lupus analysis neighborhood,” stated S. Sam Lim, MD, MPH, lead investigator of the Lupus Landmark Examine, and Professor of Drugs, Emory College and Chief of Rheumatology at Grady Memorial Hospital. “My hope is that with the Lupus Landmark Examine and the Lupus Nexus, we’ll not solely have higher information, however we’ll be capable to higher collaborate to seek out extra therapies that can allow extra personalised take care of individuals with lupus.”
Along with the Lupus Landmark Examine, different key structural parts of the Lupus Nexus embody its medical coordinating middle, biorepository, and information/data portal. The Lupus Analysis Alliance has engaged Embleema and Azenta Life Sciences because the medical coordinating middle and biorepository, respectively. DxTerity Diagnostics, Inc. will conduct biomarker evaluation utilizing their proprietary DxCollection MicroCollection Machine and Modular Immune Profile (MIP) platform.
The Lupus Landmark Examine and Lupus Nexus are a part of the Lupus Analysis Alliance’s daring Strategic Plan for Analysis that addresses crucial wants for advancing analysis, together with defining lupus heterogeneity, stratifying sufferers by lively illness mechanism, and establishing motivated and collaborative international analysis/know-how groups.
The Lupus Landmark Examine will start enrolling in choose educational medical facilities within the Lupus Therapeutics Lupus Scientific Investigators Community (LuCIN) later this 12 months with expanded roll-out in 2024. To seek out out extra details about the Lupus Landmark Examine, please contact the Lupus Nexus staff at [email protected]